Melanoma vaccine - Targeted Genetics

Drug Profile

Melanoma vaccine - Targeted Genetics

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator Targeted Genetics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 25 Oct 2000 Discontinued-I for Malignant melanoma in USA (Unknown route)
  • 21 Nov 1996 New profile
  • 21 Nov 1996 Phase-I clinical trials for Malignant melanoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top